BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 12967135)

  • 1. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial.
    Meluch AA; Greco FA; Gray JR; Thomas M; Sutton VM; Davis JL; Kalman LA; Shaffer DW; Yost K; Rinaldi DA; Hainsworth JD
    Cancer J; 2003; 9(4):251-60. PubMed ID: 12967135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial.
    Meluch AA; Hainsworth JD; Gray JR; Thomas M; Whitworth PL; Davis JL; Greco FA
    Cancer J Sci Am; 1999; 5(2):84-91. PubMed ID: 10198730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Meluch AA; McClurkan S; Gray JR; Stroup SL; Burris HA; Yardley DA; Bradof JE; Yost K; Ellis JK; Greco FA
    Cancer J; 2002; 8(4):311-21. PubMed ID: 12184409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.
    Zemanova M; Petruzelka L; Pazdro A; Kralova D; Smejkal M; Pazdrova G; Honova H
    Dis Esophagus; 2010 Feb; 23(2):160-7. PubMed ID: 19515190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel, carboplatin, and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: preliminary results of phase II trial.
    Hainsworth JD; Meluch AA; Greco FA
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-38-S19-42. PubMed ID: 9427264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer.
    van de Schoot L; Romme EA; van der Sangen MJ; Creemers GJ; van Lijnschoten G; van Driel OJ; Rutten HJ; Nieuwenhuijzen GA
    Ann Surg Oncol; 2008 Jan; 15(1):88-95. PubMed ID: 17896144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus.
    Heath EI; Burtness BA; Heitmiller RF; Salem R; Kleinberg L; Knisely JP; Yang SC; Talamini MA; Kaufman HS; Canto MI; Topazian M; Wu TT; Olukayode K; Forastiere AA
    J Clin Oncol; 2000 Feb; 18(4):868-76. PubMed ID: 10673530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
    Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer.
    Kleinberg L; Knisely JP; Heitmiller R; Zahurak M; Salem R; Burtness B; Heath EI; Forastiere AA
    Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):328-34. PubMed ID: 12738305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma.
    Czito BG; Kelsey CR; Hurwitz HI; Willett CG; Morse MA; Blobe GC; Fernando NH; D'Amico TA; Harpole DH; Honeycutt W; Yu D; Bendell JC
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1002-7. PubMed ID: 17197129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer.
    Kim DW; Blanke CD; Wu H; Shyr Y; Berlin J; Beauchamp RD; Chakravarthy B
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):397-404. PubMed ID: 17097833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
    Weiner LM; Colarusso P; Goldberg M; Dresler C; Coia LR
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-93-S19-95. PubMed ID: 9427276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
    Ajani JA; Komaki R; Putnam JB; Walsh G; Nesbitt J; Pisters PW; Lynch PM; Vaporciyan A; Smythe R; Lahoti S; Raijman I; Swisher S; Martin FD; Roth JA
    Cancer; 2001 Jul; 92(2):279-86. PubMed ID: 11466680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial.
    Keresztes RS; Port JL; Pasmantier MW; Korst RJ; Altorki NK
    J Thorac Cardiovasc Surg; 2003 Nov; 126(5):1603-8. PubMed ID: 14666040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative low-dose weekly cisplatin and continuous infusion fluorouracil plus hyperfractionated radiotherapy in stage II-III esophageal carcinoma.
    Caro M; Font A; Comas S; Viciano M; Remon J; Céliz P; Robles J; Musulén E; Sendrós MJ; Mesalles E; Jiménez JA; Boix J; Arellano A; Fernández-Llamazares J
    Clin Transl Oncol; 2016 Nov; 18(11):1106-1113. PubMed ID: 26856597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: a phase I report.
    Goldberg M; Farma J; Lampert C; Colarusso P; Coia L; Frucht H; Goosenberg E; Beard M; Weiner LM
    J Thorac Cardiovasc Surg; 2003 Oct; 126(4):1168-73. PubMed ID: 14566264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensification.
    Seung SK; Smith JW; Molendyk J; Bader SB; Phillips M; Regan J; Louie J; Soo E; Seligman M; Ruzich J; Skokan L; Ross HJ
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):13-9. PubMed ID: 15726517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial.
    Messager M; Mirabel X; Tresch E; Paumier A; Vendrely V; Dahan L; Glehen O; Vasseur F; Lacornerie T; Piessen G; El Hajbi F; Robb WB; Clisant S; Kramar A; Mariette C; Adenis A
    BMC Cancer; 2016 May; 16():318. PubMed ID: 27194176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.